JCM
LJPC

Jafra Capital Management’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Jafra Capital Management’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-12,018
Closed -$358K – 123
2018
Q1 		$358K Sell
12,018
-17,982
-60% -$580K 0.11% 79
2017
Q4 		$965K Buy
30,000
+21,137
+238% +$691K 0.27% 71
2017
Q3 		$308K Buy
8,863
+37
+0.4% +$1.19K 0.11% 70
2017
Q2 		$263K Buy
+8,826
New +$253K 0.1% 70

Other funds holding LJPC

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Jafra Capital Management's LJPC Position: Q2 2018 in Review

Jafra Capital Management sold out of La Jolla Pharmaceutical Company (LJPC) in Q2 2018, closing a stake of 12,018 shares — an estimated $358K sold.

Jafra Capital Management first reported a position in LJPC in Q2 2017 and held it in 4 quarters. The position peaked at $965K in Q4 2017. 95 funds tracked by Wall St. Rank hold LJPC as of Q2 2018.

  • Jafra Capital Management reported no remaining La Jolla Pharmaceutical Company position as of Q2 2018 after selling out during the quarter.
  • Jafra Capital Management sold 12,018 La Jolla Pharmaceutical Company shares in Q2 2018, an estimated $358K.
  • Jafra Capital Management first reported a position in La Jolla Pharmaceutical Company in Q2 2017 and held it in 4 quarters.
  • Jafra Capital Management's La Jolla Pharmaceutical Company position peaked at $965K in Q4 2017.
  • 95 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q2 2018.

Based on Jafra Capital Management's 13F filing for Q2 2018, filed 15 Aug 2018.